1/21/2021 7:12:18 AM
INmune Bio: XPro1595 To Decrease Neurodegeneration Biomarkers In Alzheimer’s Disease In Phase 1b Trial
10/5/2020 9:15:25 AM
INmune Bio To Present Data From Phase Ib Study Of Neuroinflammation In Alzheimer's Disease
5/14/2020 9:07:31 AM
INmune Bio Q1 Loss/Shr $0.19 Vs Loss $0.20 Last Year
1/2/2020 9:10:51 AM
INmune Bio Announces Publication Of New Positive Data In Journal
9/23/2019 9:06:42 AM
INmune Bio To Present XPro1595 For Treating Neuroinflammation In Alzheimer’s Disease
9/12/2019 8:40:10 AM
INmune Bio Announces USPTO Allowance Of Key Patent Covering Its DN-TNFa Platform Technology For Treating Cancer
9/4/2019 9:38:40 AM
INmune Bio To Introduce NeuLiv Program For Treatment Of NASH
5/16/2019 9:12:24 AM
INmune Bio Announces Common Stock Purchase Agreement With Lincoln Park Capital
5/15/2019 9:06:39 AM
INmune Bio Q1 Net Loss $1.9 Mln Vs. $2.8 Mln Prior Year